Logo
mobilemenu
close
CMN Live
CMN+
Home
Clinical Trials
CRISPRMED
CRISPRMED24
CRISPRMED25
CRISPRMED26
CRISPRMED Global - Brazil 2026
CRISPRMED Website Policies
EGMEDC
CMN Jobs
Job Upload Form
Webinars
CMN Webinars On-demand - All
CMN Webinar - Disrupting the Care of Cardiovascular Disease With Single-Course Gene Editing Medicines
CMN Webinar - Taking the Guesswork Out of Drug Development: CRISPR-Select Validates Drug Targets and Drug Responders Early and Conclusively
CMN Webinar - Clinical-Grade gRNA for Genomic Medicines: Making Sense of the CRISPR Regulatory Landscape
CMN Webinar - Enhancing T Cell Function for Cancer immunotherapy With CRISPR
CMN Webinar - Engineering Approaches to Improve CRISPR Technologies
CMN Webinar - Development of CRISPR/Cas9-based Therapies against Alzheimer's Disease
CMN Webinar - Epigenomic Editing Ameliorates Detrimental Effects of Adolescent Alcohol Exposure
CMN Webinar - Gene Editing for Junctional Epidermolysis Bullosa
CMN Webinar - Multiplexed Genome Regulation In Vivo with Hyper-efficient Cas12a
CMN Webinar - The TCR Therapy Revival
CMN Webinar - Deliver CRISPR to the Brain - A New Treatment Strategy for Mucopolysaccharidoses
CMN Webinar - Controllable Genome Editing With Split-Engineered Base Editors
CMN Webinar - CRISPR-based Control of Insect-borne Diseases
CMN Webinar - CRISPR and MLD
CMN Webinar - CRISPR Off-Targets II
CMN Webinar - Rare Diseases and CRISPR
CMN Webinar - CRISPR On/Off Target
CMN Webinar - CRISPR Off-Targets
CMN Webinar - CRISPR Delivery Systems
CMN Webinar - Certainty After CRISPR
Advertising
WDC
About
search
Selfservice
|
Subscriberlogin
Logout
Prime Editors
Base Editors
Delivery
Safety
Off-target
Microbiome
CAR-T
TIL
Rare Diseases
Trials
Explainers
CMN Weekly
CARBON
CorrectSequence Therapeutics
Beta-Thalassemia, BT, (NCT06024876)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion-dependent Beta-Thalassemia, TDT, (NCT06065189)
Sponsors:
Children's Hospital of Fudan University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion-dependent Beta-Thalassemia, TDT, (NCT06291961)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT06328764)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT06565026)
Sponsors:
CorrectSequence Therapeutics Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine